Chondrosarcoma natural history: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Chondrosarcoma}} | {{Chondrosarcoma}} | ||
{{CMG}};{{AE}} {{Rohan}} | {{CMG}}; {{AE}} {{Rohan}} | ||
==Overview== | ==Overview== | ||
Complications that can develop as a result of chondrosarcoma are [[metastasis]] and recurrence. The prognosis of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis. Chondrosarcoma is associated with a 5 year survival rate of | Complications that can develop as a result of chondrosarcoma are [[metastasis]] and recurrence. The prognosis of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis. Chondrosarcoma is associated with a 5 year survival rate of 70%. The presence of grade 3 lesions are associated with a particularly poor prognosis. | ||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
| Line 22: | Line 22: | ||
**Grade III tumors - 29% survival at 5 years | **Grade III tumors - 29% survival at 5 years | ||
*Depending upon the subtype, prognosis vary substantially:<ref>Dorfman HD, Czerniak B. Bone Tumors. St Louis: Mosby; 1998. 353-440.</ref> | *Depending upon the subtype, prognosis vary substantially:<ref>Dorfman HD, Czerniak B. Bone Tumors. St Louis: Mosby; 1998. 353-440.</ref> | ||
**Clear cell chondrosarcoma | **Clear cell chondrosarcoma: 70% survival rate at 5 years. | ||
**Myxoid chondrosarcoma: 70% survival rate at 5 years. | **Myxoid chondrosarcoma: 70% survival rate at 5 years. | ||
**Mesenchymal chondrosarcoma: < 50% survival rate at 5 years. | **Mesenchymal chondrosarcoma: < 50% survival rate at 5 years. | ||
| Line 31: | Line 31: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
Revision as of 20:36, 22 January 2019
|
Chondrosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Chondrosarcoma natural history On the Web |
|
American Roentgen Ray Society Images of Chondrosarcoma natural history |
|
Risk calculators and risk factors for Chondrosarcoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rohan A. Bhimani, M.B.B.S., D.N.B., M.Ch.[2]
Overview
Complications that can develop as a result of chondrosarcoma are metastasis and recurrence. The prognosis of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis. Chondrosarcoma is associated with a 5 year survival rate of 70%. The presence of grade 3 lesions are associated with a particularly poor prognosis.
Natural History, Complications, and Prognosis
Complications
- Chondrosarcoma may metastatize to other organs.[1]
- Lung is the most common location for metastatic disease.
- Chondrosarcoma can rarely metastatize to skin.[1]
- Chondrosarcoma may recur and may need treatment with surgery, chemotherapy or radiation.
- Unlike other cancers, chondrosarcoma can return many years later.
- Follow up scans are extremely important for chondrosarcoma to make sure there has been no recurrence or metastasis.
Prognosis
- The prognosis of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis.[2]
- Prognosis varies with grade:[3]
- Grade I tumors - 90% survival at 5 years
- Grade II tumors - 81% survival at 5 years
- Grade III tumors - 29% survival at 5 years
- Depending upon the subtype, prognosis vary substantially:[4]
- Clear cell chondrosarcoma: 70% survival rate at 5 years.
- Myxoid chondrosarcoma: 70% survival rate at 5 years.
- Mesenchymal chondrosarcoma: < 50% survival rate at 5 years.
- Dedifferentiated chondrosarcoma: 10% survival rate after 1 year.
- Prognosis varies with location:[5]
- Long bones have a better prognosis than axial skeleton.
References
- ↑ 1.0 1.1 Lalam RK, Cassar-Pullicino VN, Kumar N, Cool WP, Cribb GL, Mangham DC (2015). "Subcutaneous and lung metastases from chondrosarcoma of the thumb". BJR Case Rep. 1 (3): 20150129. doi:10.1259/bjrcr.20150129. PMC 6180831. PMID 30363596.
- ↑ Larramendy ML, Mandahl N, Mertens F, Blomqvist C, Kivioja AH, Karaharju E; et al. (1999). "Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas". Hum Pathol. 30 (10): 1247–53. PMID 10534175.
- ↑ Evans HL, Ayala AG, Romsdahl MM (1977). "Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading". Cancer. 40 (2): 818–31. PMID 890662.
- ↑ Dorfman HD, Czerniak B. Bone Tumors. St Louis: Mosby; 1998. 353-440.
- ↑ Peabody, Terrance (2014). Orthopaedic oncology : primary and metastatic tumors of the skeletal system. Cham: Springer. ISBN 9783319073224.